Brief: Cue Biopharma Updates on CUE-101 at DAVA 4th Hawaii Summit
01/07/2025 21:13
July 1 (Reuters) - Cue Biopharma Inc CUE.O: CUE BIOPHARMA PROVIDES UPDATE ON MOST ADVANCED CLINICAL STAGE ASSET, CUE-101, PRESENTED BY DR. DIMITRIOS COLEVAS AT THE DAVA 4TH HAWAII GLOBAL SUMMIT ON THORACIC MALIGNANCIES CUE BIOPHARMA INC - ORR OF 50% IN HPV+ R/M HNSCC PATIENTS CUE BIOPHARMA INC - 12-MONTH SURVIVAL OF 88% AND MOS OF 32 MONTHS Source text: ID:nGNX9PRPqp Further company coverage: CUE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cue Biopharma
See all newsU.S. STOCKS ON THE MOVE-Insmed, Marvell, Meta
US STOCKS ON THE MOVE-Meta, Marvell Technology, Insmed
U.S. STOCKS ON THE MOVE-Accenture, Arhaus, Alkermes
Cue Biopharma surges after positive results from mid-stage study for CUE-221
Brief: Cue Biopharma Announces Positive Topline Results From Cue-221 Phase 2 Study In Chronic Spontaneous Urticaria